10-Q: CapsoVision Q3 2025: Revenue Growth Amidst Rising Losses

CapsoVision reports increased Q3 2025 revenue driven by CapsoCam Plus sales, but faces substantial doubt about its going concern ability due to continued net losses and negative cash flows.

Summary

• Net revenue for the three months ended September 30, 2025, increased by 19% to $3.5 million, and for the nine months, it grew by 16% to $9.6 million, primarily due to increased CapsoCam Plus capsule sales.
• Gross profit increased by 16% to $1.9 million for Q3 2025 and by 12% to $5.2 million for the nine months, but gross margin declined from 56% to 54% due to competitive pricing and increased customs/tariffs.
• Operating expenses surged, with Research and Development up 35% to $6.1 million for Q3 2025 and General and Administrative up 74% to $2.1 million for Q3 2025, contributing to increased net losses.
• The company reported a net loss of $7.9 million for Q3 2025 and $17.9 million for the nine months ended September 30, 2025, an increase of 37% and 17% respectively, compared to the prior year periods.
• As of September 30, 2025, the accumulated deficit reached $148.3 million, and the company had cash and cash equivalents of $17.8 million.
• Management expressed substantial doubt about the company's ability to continue as a going concern within one year, indicating that IPO proceeds of $23.4 million are likely insufficient to fund future expenditures.
• FDA submission for the CapsoCam Plus with AI technology is delayed to year-end 2025, and the submission for the second-generation CapsoCam Colon is now planned for Q2 2026, with clearance targeted for Q4 2026.
• The company entered into a development agreement with Canon Inc. for CMOS image sensor samples, with an initial payment of $1.0 million made in July 2025 and a remaining commitment of $2.5 million.

Sentiment

Score: 3

Explanation: While revenue growth is positive and an IPO was completed, the company's significant and increasing net losses, negative cash flow, explicit 'going concern' warning, and delays in key product regulatory submissions indicate substantial operational and financial challenges. The need for additional capital with no certainty of obtaining it on favorable terms adds significant risk.

Positives

• Net revenue increased by 19% to $3.5 million for the three months ended September 30, 2025, and by 16% to $9.6 million for the nine months ended September 30, 2025.
• Unit sales of CapsoCam Plus capsules increased by 20% for the three months and 17% for the nine months ended September 30, 2025.
• Successfully completed an Initial Public Offering (IPO) in July 2025, raising approximately $23.4 million in net proceeds.
• Progress in the development of CapsoCam Colon, with the second arm of the pivotal clinical study underway for the second-generation capsule.
• Submitted an FDA Breakthrough Device Designation application on November 6, 2025, for a capsule endoscopy solution targeting pancreatic cancer, which could expedite regulatory review.
• Entered into a development agreement with Canon Inc. for higher-resolution CMOS image sensor samples for future capsule versions.
• Received FDA clearance in December 2024 for pediatric use and telehealth supervision of CapsoCam Plus, expanding market reach.

Negatives

• Reported a net loss of $7.9 million for the three months ended September 30, 2025, and $17.9 million for the nine months, representing a 37% and 17% increase, respectively, compared to prior year periods.
• Accumulated deficit grew to $148.3 million as of September 30, 2025.
• Net cash used in operating activities was $15.2 million for the nine months ended September 30, 2025.
• Gross margin declined from 56% to 54% for both the three and nine months ended September 30, 2025, attributed to competitive pricing pressures and increased customs/tariffs.
• Operating expenses, particularly Research and Development (up 35% for Q3 2025) and General and Administrative (up 74% for Q3 2025 and 85% for 9M 2025), increased significantly.
• Management explicitly stated "substantial doubt about the Company's ability to continue as a going concern within one year" after the financial statements' issuance date.
• Identified two material weaknesses in internal control over financial reporting related to IT general controls and segregation of duties.
• FDA submission for CapsoCam Plus with AI technology is delayed to year-end 2025 due to biostatistician resource constraints.
• FDA submission for the second-generation CapsoCam Colon is delayed to Q2 2026, with clearance targeted for Q4 2026, pushing back commercialization expectations.

Risks

• History of net losses and expectation of additional losses in the foreseeable future.
• Substantial doubt about the ability to continue as a going concern and the need to raise additional financing.
• Reliance on CapsoCam Plus for small bowel sales in the near-term and risks in executing revenue growth strategy.
• CapsoCam Colon revenue not expected until Q4 2026, dependent on FDA clearance for the second generation.
• Broad adoption of CapsoCam Colon depends on expanding the indicated patient population, increasing accuracy, and achieving satisfactory completion rates.
• Longer-term efforts to expand GI-tract capsule endoscopy solutions beyond small bowel and colon pathologies may not succeed.
• Potential delays or failure to obtain 510(k) clearance for CapsoCam Colon (initial and second generation) and AI-enhanced CapsoCam Plus.
• Failure or defect in GI-tract capsule endoscopy solution could harm reputation, expose to liability, and reduce sales.
• Reliance on single-source suppliers located in Asia (Taiwan and Japan) for critical components, posing supply chain disruption risks.
• Exposure to substantial geopolitical and trade risks (e.g., China-Taiwan tensions, tariffs) and natural disaster risks in Asia.
• Inadequate reimbursement from Medicare and other third-party payors for products.
• Expansion risks when expanding in existing and entering into new foreign markets.
• Clinical results of various clinical studies may not be released in peer-reviewed publications, hindering medical community acceptance.
• Risks associated with the use and development of artificial intelligence, including accuracy, clinician reliance, data quality, and evolving regulatory landscape.
• Actual or perceived failures to comply with applicable data privacy and security laws (e.g., HIPAA, GDPR).
• Operating in a highly competitive industry with established players (Medtronic, Ankon) and aggressive pricing from Asia-based companies.
• Cost-containment efforts of customers and group purchasing organizations could adversely affect sales and results of operations.
• Effectiveness of CapsoCam capsules relies heavily on patients adhering to use protocols (diet, bowel cleansing, manual retrieval).
• Risks associated with CapsoCam capsules, including capsule retention, component failures, and aspiration.
• Challenges for the existing sales and marketing team to effectively sell additional products and features.
• Non-compliance with regulatory requirements (e.g., FDA cGMPs, federal and state anti-kickback and false claims laws, FCPA) could lead to penalties.
• Dependence on the efforts of senior management and key personnel, and the ability to retain and attract them.
• Product and professional liability suits could result in expensive litigation and substantial damages.
• Potential for acquisitions to disrupt business, cause dilution, and reduce financial resources.
• Macroeconomic conditions (inflation, geopolitical instability, interest rates) could adversely affect business.
• Healthcare policy changes and funding/budgetary changes could materially adversely affect the business.
• Adverse developments affecting the financial services industry could impact business operations.
• Limitations on the ability to utilize net operating loss carryforwards and research and development tax credits.
• Relationships with board-certified physicians are subject to various state laws and compliance risks.
• Information technology system failures, cyberattacks, or deficiencies in cybersecurity.
• Litigation and other risks as a result of identified material weaknesses in internal control over financial reporting.
• Inability to obtain, maintain, enforce, and protect intellectual property rights (patents, trademarks, trade secrets).
• Expiration of patents and reduction or elimination of patent protection.
• Changes in U.S. or foreign patent laws or their interpretations could diminish the value of patents.
• Claims challenging the inventorship or ownership of patents and other intellectual property rights.
• Reliance on third-party open source software components and risks of non-compliance with licenses.
• Dependence on Aureliance, an authorized agent and importer, for a significant portion of revenue from EU/EEA countries.
• Market price volatility of common stock, reduced reporting requirements as an emerging growth company/smaller reporting company, increased costs as a public company, no dividends in the foreseeable future, dilution from future capital raises, and potential sales of substantial shares by existing stockholders.

Future Outlook

The company plans to increase small bowel capsule sales by retaining and growing its customer base, expanding sales teams, pursuing the pediatric market, introducing complementary products (capsule delivery device, patency capsule), and facilitating telemedicine adoption. It anticipates submitting the 510(k) application for CapsoCam Plus with AI by year-end 2025, targeting mid-2026 FDA clearance. The FDA submission for the second-generation CapsoCam Colon is planned for Q2 2026, with a goal of obtaining 510(k) clearance in Q4 2026. Longer-term, the company aims to adapt its CapsoCam products for new GI indications like esophageal medical conditions and pancreatic cancer, having submitted an FDA Breakthrough Device Designation application for pancreatic cancer. The company expects to continue incurring losses and negative cash flows in the foreseeable future as it scales its business and invests in R&D.

Management Comments

• "We expect to continue to experience similar circumstances until existing and future products sales yield further growth in revenues, achievement of break-even, and realization of future operating income, net income, and positive operating cash flows."
• "While the Company completed the IPO in July 2025 and raised approximately $23.4 million in net proceeds, it is not probable that these funds are sufficient to fund expenditures necessary to achieve sales growth and innovation objectives."
• "The Company intends to consummate additional capital raising activities, there is no certainty as to such capital raising activities occurring at all, or occurring with sufficient timing or magnitude, sufficient to alleviate such substantial doubt."
• "Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world."
• "We are working closely with FDA on addressing their review follow-up inquiries about the abovementioned 510(k) for the First-Generation Product. Based on the FDA comments received so far, we are refining the second arm study."
• "To mitigate further delays [in AI-enhanced CapsoCam Plus submission], we have contracted with an additional biostatistical consulting group."

Industry Context

CapsoVision operates in the highly competitive medical technology industry, specifically in diagnostic imaging and endoscopic procedures, characterized by rapid technological advancements. The company faces strong competition from established players like Medtronic, which has a first-mover advantage in capsule endoscopy and greater resources, and other companies like Ankon, which has already launched an FDA-cleared AI product for small bowel. CapsoVision's strategy to integrate AI into its CapsoCam Plus and develop CapsoCam Colon aims to differentiate its offerings, but it faces challenges in market penetration and regulatory clearances against these competitors. The industry is also influenced by cost-containment efforts from healthcare providers and GPOs, and evolving regulatory frameworks for AI technologies and data privacy.

Comparison to Industry Standards

• CapsoVision's CapsoCam Plus competes with traditional enteroscopy procedures and other capsule-based imaging solutions from companies like Medtronic, IntroMedic, JinShan, and Ankon.
• Medtronic's PillCam COLON 2, introduced in 2014, is the only other U.S. FDA approved colon capsule endoscopy, giving it a significant first-mover advantage over CapsoVision's in-development CapsoCam Colon.
• Ankon (through AnX Robotics) has an FDA-cleared AI-driven capsule endoscopy analysis software (NaviCam ProScan, introduced in 2023) for small bowel, which serves as a predicate device for CapsoVision's AI-enhanced CapsoCam Plus, placing CapsoVision at a market disadvantage until its own AI product launches.
• CapsoCam Colon's successful completion rate is supported by a physical design encouraging timely GI-tract transit and a battery lifetime twice that of competitors, but it still faces challenges similar to traditional colonoscopies regarding bowel preparation.
• Pricing strategies from Asia-based competitors like Ankon, Jinshan, and IntroMedic, who offer products at lower-than-average prices, exert pressure on CapsoVision's profit margins.

Management Changes

Corporate Governance

Legal Proceedings

• Not a party to any material litigation, arbitration, claims, or proceedings as of September 30, 2025, and December 31, 2024.

Related Party Transactions

• On May 27, 2025, the company entered into a promissory note with Ching-Hang Shen, a beneficial owner of more than 5% of the company's outstanding common stock, for $1.0 million at 1% interest per month. The note was repaid in cash on July 11, 2025, and 7,508 shares of common stock were issued to Mr. Shen on July 7, 2025, at a fair value of $31,000 as consideration.
• Incurred R&D expenses of $298,000 for the three months and $960,000 for the nine months ended September 30, 2025, for non-recurring engineering services with an R&D and manufacturing services vendor that holds an insignificant percentage of the company's capital stock. The outstanding balance was included in Accrued Expenses and Other Current Liabilities.

Stakeholder Impact

• Shareholders: Face significant dilution risk from potential future capital raises and the possibility of losing all or part of their investment due to the 'going concern' doubt. The stock price may be volatile due to financial performance and market conditions.
• Employees: Changes in management roles and new hires indicate ongoing organizational adjustments. Stock-based compensation is a significant component of overall compensation, but the value is tied to stock performance.
• Customers: May benefit from new and enhanced products like CapsoCam Colon and AI-enhanced CapsoCam Plus, but product delays could impact availability. Reliance on patient adherence for capsule effectiveness remains a factor.
• Suppliers: The company's reliance on single-source suppliers in Asia, particularly Taiwan and Japan, exposes them to geopolitical and supply chain risks, which could affect product availability and costs.
• Creditors: The 'going concern' doubt raises concerns about the company's ability to meet its financial obligations in the long term, despite recent IPO proceeds.

Next Steps

• Continue efforts to penetrate the small bowel capsule endoscopy market, including retaining and growing the customer base, increasing sales team effectiveness, and pursuing the pediatric market.
• Introduce complementary products such as a capsule delivery device (expected Q1 2026) and a patency capsule (FDA 510(k) submission planned Q1 2026).
• Submit the 510(k) application to the FDA for CapsoCam Plus with AI technology by year-end 2025, targeting mid-2026 FDA clearance.
• Complete the second arm of the CapsoCam Colon pivotal study and submit the 510(k) application to the FDA in Q2 2026, with a goal of obtaining clearance in Q4 2026.
• Commence feasibility studies for esophageal varices in the second half of 2026.
• Commence feasibility studies for pancreatic cancer in the first half of 2026, following the FDA Breakthrough Device Designation application.
• Continue investing in AI to improve pathology detection and classification accuracy and streamline diagnostic processes.
• Address material weaknesses in internal control over financial reporting, including evaluating accounting personnel, replacing the ERP system, and formalizing IT and business process controls.
• Evaluate strategies to obtain additional funding for future operations, potentially through public and private placements of equity and/or debt securities.

Key Dates

Recommendation

The company's explicit disclosure of "substantial doubt about its ability to continue as a going concern" within the next year, despite a recent IPO, is a critical red flag. While revenue is growing, net losses are increasing, and gross margins are declining. Delays in FDA submissions for key pipeline products (CapsoCam Colon and AI-enhanced CapsoCam Plus) further push out potential profitability. The need for additional capital, with no certainty of obtaining it on favorable terms, adds significant risk. The material weaknesses in internal controls also raise concerns about financial reporting reliability. For a seasoned investor, these factors collectively point to a highly speculative investment with significant downside risk, warranting a "sell" recommendation.

Keywords

CapsoVision, Capsule Endoscopy, Medical Technology, GI Imaging, CapsoCam Plus, CapsoCam Colon, FDA Clearance, AI Technology, Financial Results, SEC Filing, 10-Q, Going Concern, Net Loss, Revenue Growth, R&D Expenses, Operating Expenses, Intellectual Property, Supply Chain, Regulatory Risk, Healthcare Industry, Biomedical, Diagnostics